Cancer immunotherapy employing immune checkpoint blockade (ICB), encompassing antibodies that impede cytotoxic T lymphocyte protein 4 (CTLA-4) and programmed cell death protein 1 [PD-(L)1], has enhanced the outcomes for cancer patients. This evidence concerns the gene PDCD1 and cancer.